ApoGen increases 2016 Series A funding round to $11 million
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
New European investor Octopus Ventures led the Series B round with participation from another new backer, M Ventures — the Amsterdam-based, strategic, corporate venture capital arm of Merck KGaA, in Darmstadt, Germany